Programmed death‐ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer

Immune checkpoint inhibitor therapy has been clinically introduced for several malignancies, and its effectiveness has been confirmed by clinical trials. In particular, programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) are widely known as important immune checkpoint molecu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Autores principales: Amatatsu, Masahiko, Arigami, Takaaki, Uenosono, Yoshikazu, Yanagita, Shigehiro, Uchikado, Yasuto, Kijima, Yuko, Kurahara, Hiroshi, Kita, Yoshiaki, Mori, Shinichiro, Sasaki, Ken, Omoto, Itaru, Maemura, Kosei, Ishigami, Sumiya, Natsugoe, Shoji
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834808/
https://ncbi.nlm.nih.gov/pubmed/29345842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13508
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares